Article3 Biotech2025
Exploring the therapeutic efficacy of Bai-Shao in mitigating comorbid epileptic seizures and cognitive impairment via inflammatory signaling pathways: insights from in silico and in vivo studies.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bai-Shao (BS) ingredients capable of crossing the blood-brain barrier (BBB) were identified and analyzed for their main gene targets. Genes associated with epileptic seizures (ES), cognitive impairment (CI), and inflammation were retrieved, with common targets between BS and these conditions determined via Venn analysis. Protein-protein interaction (PPI) analysis identified the top 10 key genes, whose correlations with apolipoprotein E (APOE) and methylenetetrahydrofolate reductase (MTHFR) were assessed. Functional pathways were explored using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG), while molecular docking evaluated interactions between BS compounds and target proteins. Findings were validated in a pentylenetetrazol (PTZ)-induced mouse model. BS contains β-sitosterol and betulinic acid, both BBB-permeable, with 277 shared ES/CI-related targets identified. The top 10 genes correlated with APOE and MTHFR, and pathway analysis highlighted interleukin-17 (IL-17) and tumor necrosis factor (TNF) signaling, involving FOS proto-oncogene (FOS), jun proto-oncogene (JUN), caspase-3 (CASP3), phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), and cyclooxygenase-2 (COX2). Behavioral tests, including the Open Field Test and Morris Water Maze, indicated cognitive and motor improvements in PTZ-treated mice. Molecular analysis revealed hippocampal regulation of key genes and altered TNF-alpha (TNFα), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β) levels. In conclusion, BS demonstrates therapeutic potential for comorbid ES and CI by modulating inflammatory pathways and cell survival mechanisms, supporting its role in neurological research. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-025-04316-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.